DEA Scheduling Delays Can Be Reduced With Early Studies, Frequent Sharing
Executive Summary
Early interactions with FDA and the Drug Enforcement Administration may help drug sponsors avoid a long lag time between NDA approval and controlled substance scheduling, industry and agency experts said at the Food and Drug Law Institute’s annual meeting.
You may also be interested in...
AstraZeneca’s Movantik Clears FDA; Launch On Hold Pending DEA Action
Naloxegol is currently a Schedule II controlled substance due to its structural similarity to another compound; AstraZeneca seeks descheduling of the constipation drug, which labeling states poses no risk of abuse or dependency.
Opioid Sponsors To Get Help Developing Abuse-Resistant Products From FDA, NIH
Additional research into abuse-deterrent and non-addictive drug formulations is expected as part of the Obama Administration’s prescription drug abuse plan, some of which already is under way.
Tamper-Resistance Could Allow New Opioid Formulations To Differentiate Themselves
A claim for tamper-resistance rather than broad abuse-deterrence appears to be the immediate path forward for companies seeking to differentiate a new opioid product by its ability to impede recreational use.